

**Jubilant Epipad LLC**  
**Balance Sheet as at 31 March 2019**

		USD	INR (' In Thousands)
	Notes		As at 31 March 2019
<b>ASSETS</b>			
<b>Non-current assets</b>			
Intangible asset under development	1	1,651,230	114,199
<b>Total non-current assets</b>		<b>1,651,230</b>	<b>114,199</b>
<b>Current assets</b>			
Financial assets			
i. Trade receivables	2	1,651,230	114,199
<b>Total current assets</b>		<b>1,651,230</b>	<b>114,199</b>
<b>Total assets</b>		<b>3,302,460</b>	<b>228,398</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	3	1,651,230	114,298
Other equity		(2,960)	(304)
<b>Total Equity</b>		<b>1,648,270</b>	<b>113,994</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Financial liabilities			
i. Trade payables	4	1,654,190	114,404
<b>Total current liabilities</b>		<b>1,654,190</b>	<b>114,404</b>
<b>Total liabilities</b>		<b>1,654,190</b>	<b>114,404</b>
<b>Total equity and liabilities</b>		<b>3,302,460</b>	<b>228,398</b>

**Benny Thomas**  
**General Manager Finance**

Place: Bangalore  
Date: 15th May 2019

**Jubilant Epipad LLC**  
**Statement of Profit and Loss for the year ended 31 March 2019**

		USD	INR (' In Thousands)
	Notes	For the year ended 31 March 2019	
Revenue from operations		-	-
<b>Total income</b>		-	-
<b>Expenses</b>			
Other expenses	5	2,960	209
<b>Total expenses</b>		<b>2,960</b>	<b>209</b>
<b>Loss before tax</b>		<b>(2,960)</b>	<b>(209)</b>
Tax expense			
- Current tax		-	-
- Deferred tax		-	-
<b>Total tax expense</b>		-	-
<b>Loss for the year</b>		<b>(2,960)</b>	<b>(209)</b>
<b>Other comprehensive income</b>			
<b>Items that will be reclassified to profit or loss</b>			
Exchange differences on translation of foreign operations		-	(95)
<b>Other comprehensive loss for the year, net of tax</b>		-	<b>(95)</b>
<b>Total comprehensive loss for the year</b>		<b>(2,960)</b>	<b>(304)</b>

**Benny Thomas**  
**General Manager Finance**

Place: Bangalore

Date: 15th May 2019

**Jubilant Epipad LLC**  
**Statement of changes in Equity for the year ended 31 March 2019**

**A) Equity share capital**

**USD**

<b>Balance as at 1 April 2018</b>	<b>-</b>
Additions during the year	1,651,230
<b>Balance as at 31 March 2019</b>	<b>1,651,230</b>

**B) Other Equity**

**USD**

	<b>Reserves and Surplus</b>	
	<b>Retained earnings</b>	<b>Total</b>
<b>Balances as at 1 April 2018</b>	<b>-</b>	<b>-</b>
Loss for the year	(2,960)	(2,960)
<b>Total comprehensive loss for the year</b>	<b>(2,960)</b>	<b>(2,960)</b>
<b>Balances as at 31 March 2019</b>	<b>(2,960)</b>	<b>(2,960)</b>

**Benny Thomas**  
**General Manager Finance**

Place: Bangalore

Date: 15th May 2019

**Jubilant Epipad LLC**  
**Statement of changes in Equity for the year ended 31 March 2019**

**A)Equity share capital**

	INR (' In Thousands)
<b>Balance as at 1 April 2018</b>	-
Additions during the year	114,298
<b>Balance as at 31 March 2019</b>	<b>114,298</b>

**B)Other Equity**

	Reserves and Surplus	Other Comprehensive Income	INR (' In Thousands)
	Retained earnings	Foreign currency translation reserve	Total
<b>Balances as at 1 April 2018</b>	-	-	-
Loss for the year	(209)	-	(209)
Other comprehensive loss	-	(95)	(95)
<b>Total comprehensive loss for the year</b>	<b>(209)</b>	<b>(95)</b>	<b>(304)</b>
<b>Balances as at 31 March 2019</b>	<b>(209)</b>	<b>(95)</b>	<b>(304)</b>

**Benny Thomas**  
**General Manager Finance**

Place: Bangalore  
Date: 15th May 2019

**Jubilant Epipad LLC****Statement of Cash Flows for the year ended 31 March 2019**

	USD	INR (' In Thousands)
<b>For the year ended 31 March 2019</b>		
<hr/>		
<b>A. Cash flow from operating activities</b>		
Loss before tax	(2,960)	(209)
<b>Operating cash flow before working capital changes</b>	<u>(2,960)</u>	<u>(209)</u>
Increase in trade and other receivables	(1,651,230)	(114,199)
Increase in trade payables, provisions and other liabilities	1,654,190	114,404
<b>Cash used in operations</b>	-	(4)
Income tax and wealth tax paid (net of refund)	-	-
<b>Net cash used in operating activities</b>	<u>-</u>	<u>(4)</u>
<b>B. Cash flow from investing activities</b>		
<b>Net cash generated from / (used in) investing activities</b>	<u>-</u>	<u>-</u>
<b>C. Cash flow arising from financing activities</b>		
<b>Net cash generated from financing activities</b>	<u>-</u>	<u>-</u>
<b>D. Effect of exchange rate changes</b>	-	4
<b>Net decrease in cash and cash equivalents (A+B+C+D)</b>	-	-
Add: cash and cash equivalents at the beginning of year	-	-
<b>Cash and cash equivalents at the end of the year</b>	<u>-</u>	<u>-</u>

**Benny Thomas****General Manager Finance**

Place: Bangalore

Date: 15th May 2019

**Jubilant Epipad LLC****Notes to the financial statements for the year ended 31 March 2019****Note 1: Intangible asset under development**

	USD	INR (' In Thousands)
		As at 31 March 2019
Intangible asset under development	1,651,230	114,199
<b>Total Intangible asset under development</b>	<b>1,651,230</b>	<b>114,199</b>

**Note 2: Trade receivables**

	USD	INR (' In Thousands)
		As at 31 March 2019
<b>Unsecured, considered good</b>		
Trade receivables from related parties	1,651,230	114,199
<b>Total trade receivables</b>	<b>1,651,230</b>	<b>114,199</b>

**Note 3: Equity share capital**

	USD	INR (' In Thousands)
		As at 31 March 2019
<b>Issued, subscribed and paid up</b>		
Equity shares	1,651,230	114,298

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

**Jubilant Epipad LLC****Notes to the financial statements for the year ended 31 March 2019**

3) The details of shareholders holding more than 5% shares in the Company:

	<b>As at 31 March 2019</b>	
	<b>No of shares</b>	<b>% holding in the class</b>
<b>Name of the Shareholder</b>		
Jubilant Therapeutics Inc	100	100%

4) The reconciliation of the number of shares outstanding as at beginning and at end of the reporting period

	<b>As at 31 March 2019</b>		
	<b>No of shares</b>	<b>USD (Rs in thousand)</b>	
Numbers of shares at the beginning	-	-	-
Add: Shares issued during the year	100	1,651,230	114,298
Number of shares at the end	<b>100</b>	<b>1,651,230</b>	<b>114,298</b>

5) Equity shares held by holding company/ultimate holding company is set out below:

<b>Particulars</b>	<b>As at</b>	
	<b>No of shares</b>	
Jubilant Therapeutics Inc	100	

**Jubilant Epipad LLC****Notes to the financial statements for the year ended 31 March 2019****Note 4: Trade payables**

	USD	INR (' In Thousands)
		As at
		<b>31 March 2019</b>
Trade payables	2,000	138
Due to related parties	1,652,190	114,266
<b>Total trade payables</b>	<b>1,654,190</b>	<b>114,404</b>

**Note 5: Other expenses**

	USD	INR (' In Thousands)
		As at
		<b>31 March 2019</b>
Auditors remuneration	2,000	141
Legal and professional fees	960	68
<b>Total other expenses</b>	<b>2,960</b>	<b>209</b>